Date | Price Target | Rating | Analyst |
---|---|---|---|
9/4/2024 | $275.00 | Outperform | RBC Capital Mkts |
7/24/2024 | $266.00 → $242.00 | Buy → Hold | Jefferies |
6/6/2024 | $270.00 | Buy | Goldman |
2/26/2024 | $290.00 | Outperform | Leerink Partners |
2/15/2024 | Buy → Neutral | Guggenheim | |
2/13/2024 | $285.00 | Buy | BTIG Research |
11/2/2023 | $248.00 → $202.00 | Outperform → Neutral | Robert W. Baird |
9/6/2023 | $260.00 | Buy | HSBC Securities |
RBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $275.00
Jefferies downgraded IQVIA from Buy to Hold and set a new price target of $242.00 from $266.00 previously
Goldman initiated coverage of IQVIA with a rating of Buy and set a new price target of $270.00
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will recei
Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 millio
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights. IQVIA AI Assistant is a user-friendly, conversational text interface that provides immediate and intuitive analytic insights. For the first time, customers can simply ask complex questions about their business and receive comprehensive and reliable answers in moments instead of hours or days. Available insights from IQVIA AI Assistant include brand and t
Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry. Frost & Sullivan's annual Customer Value Leadership Award recognizes the company that offers products or services that customers find superior in overall price, performance and
PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, sites enjoy simplified access to trial technologies from IQVIA and other technology partners that have taken the s
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
Jefferies analyst David Windley downgrades IQVIA Hldgs (NYSE:IQV) from Buy to Hold and lowers the price target from $266 to $242.
During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:IQV), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 6 3 0 0 Last 30D 2 3 1 0 0 1M Ago 0 2 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 1 0 0 Analysts have set 12-month price targets for IQVIA Hldgs, revealing an average target of $265.62, a high estimate of $300.00, and a low estimate of $230.00. This upward trend is evident, with the current average reflecting a
Morgan Stanley analyst Tejas Savant maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and raises the price target from $270 to $280.
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)